Symbicort SMART
Phase 3
- Conditions
- Asthma
- Registration Number
- JPRN-jRCT2080220715
- Lead Sponsor
- AstraZeneca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Diagnosis of asthma according to GINA 2007 with a documented history of at least 6 months duration
- Turbuhaler-Prescribed use of inhaled GCS (any brand) for at least 12 weeksAges
- Reversible airway obstruction, defined as an increase in 12% of FEV1 or more relative to baseline for all patients 15-30 minutes after inhalation of in total 2 x 0.4 mg terbutaline
Exclusion Criteria
- Respiratory infection affecting the asthma, as judged by the investigator within 4 weeks
- Intake of oral, rectal or parenteral GCS within 4 weeks and/or depot parenteral GCS within 12 weeks
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method